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ABSTRACT
For decades, no cancer therapy had been shown
to improve average survival in metastatic
melanoma. Two critical events have occurred,
the discovery of melanoma driver mutation
subsets and the discovery of immune
checkpoint inhibitors, which have allowed for
the development of modern, effective therapies.
These findings have facilitated a rapid
emergence of novel therapeutics for the
disease with multiple FDA approvals in the last
several years. The drugs vemurafenib,
trametinib, and dabrafenib, which inhibit the
commonly mutated BRAF pathway, have been
approved based on improvements in survival
outcomes. Agents that block immune
checkpoints on lymphocytes allowing for
immune cell activity against melanoma have
also been approved based on improved survival
outcomes such as ipilimumab and nivolumab.
Pembrolizumab, another immune checkpoint
inhibitor, has also been approved based on the
response rate and duration of response in a
phase 1 trial. Further agents and combinations
of approved agents are positioned to possibly
further increase this tally of approved drugs.
This review will discuss recently approved novel
agents and select drugs in development in
advanced melanoma.
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INTRODUCTION
Melanoma has held a designation of ill repute
among cancer subtypes, being a disease that has
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been resistant to modern chemotherapeutic
approaches and results in the rapid demise of
patients who are in the prime of their life. Up
until a couple of years ago, typical treatments
included chemotherapy drugs such as
dacarbazine (DTIC) and temozolomide, which
had low response rates and no improvement in
overall survival [1]. Additionally, early attempts
at immune therapy in the form of cytokines,
such as interferon and interleukin-2 (IL-2), also
had low response rates with high toxicity levels
[2]. In the setting of these therapies, a
metastatic melanoma patient’s average survival
was 6–8 months, and no agent had been able to
improve on this outcome in numerous
randomized clinical trials [3].
Fortunately, a new generation of therapies
for metastatic melanoma has arisen in the last
few years resulting in improvements in response
rates and overall survival outcomes. These
advancements have taken place primarily on
two separate fronts: (1) molecularly targeted
inhibitors that work within the melanoma cell
against abnormally activated protein kinases
and (2) immune checkpoint inhibitors that
work by enhancing T-lymphocyte function.
Vemurafenib and ipilimumab represent the
first in class of each of these approaches,
respectively, and both agents have shown
improved average overall survival outcomes
for metastatic melanoma patients in
randomized trials. Several other agents in both
classes have subsequently emerged, continuing
to improve clinical outcomes. This review will
focus on the clinical development of modern
novel melanoma molecularly targeted agents
and immune checkpoint inhibitors, as well as
combination approaches.
This article is based on previously conducted
studies and does not involve any new studies of





Targeting the BRAF Pathway in Advanced
Melanoma
The molecular biology of melanoma is
complicated with numerous mutations present
and a variety of pathways impacted (Fig. 1).
Fig. 1 Schematic diagram showing select signaling
pathways in melanoma. With activating BRAF mutations
present in 50% of melanoma tumors and NRAS mutations
present in approximately 20%, the MAP kinase pathway
(RAS-RAF-MEK-ERK) plays an important role in the
majority of melanomas. However, other pathways also can
contribute to pathogenesis and resistance to BRAF and
MEK inhibition, such as activation of the PI3K pathway
and signaling through COT and CDK4
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However, there are common driver mutations
present at high frequencies that allow for a
molecularly targeted approach. Critical to
highlighting these common targetable
mutation events was the work of Davies et al.
in 2002 when they reported a high frequency of
BRAF gene mutation (now known to be present
in approximately 50% of melanomas), leading
to the theory that the BRAF serine/threonine
kinase could represent a commonly applicable
therapeutic target [4]. In about 80–90% of
mutated BRAF tumors, an activating V600E
missense mutation is present, while about
10–20% of BRAF mutant tumors have V600K,
V600D, and V600R mutations [5]. These
activating mutations result in constitutive
activation of the MAP (mitogen-activated
protein) kinase pathway resulting in
unchecked cell proliferation.
A landmark phase I trial of a potent BRAF
V600 inhibitor PLX-4032 (now known as
vemurafenib) demonstrated proof of principle
that this targeted therapy approach could work
[6]. This study demonstrated high response
rates and acceptable tolerability, which led to
further clinical development of the drug. A
phase III study (BRIM-3) comparing
vemurafenib with dacarbazine was performed
with co-primary endpoints of overall survival
(OS) and PFS [7]. This study included 675
patients with metastatic melanoma (95%) or
unresectable stage IIIC (5%) with a BRAF V600E
mutation who were previously untreated and
showed a statistically significant improvement
in survival for those treated with vemurafenib
compared to dacarbazine [median OS 13.6
versus 9.7 months, respectively (HR 0.70,
p = 0.0008)] [8]. The median PFS was also
significantly prolonged with vemurafenib use
at 6.9 months compared to 1.6 months for
dacarbazine (HR 0.26, p\0.001). Based on
these results, the FDA approved vemurafenib
for the treatment of BRAF V600E mutant
metastatic melanoma in 2011. An increased
incidence of cutaneous squamous cell
carcinomas and keratoacanthomas has been
noted with vemurafenib and other BRAF
inhibitor therapies. In a study that analyzed
three trials with a total of 520 patients who
received vemurafenib, the incidence of
squamous cell carcinoma was noted to be
19–26%, mostly keratoacanthomas [9]. The
majority of patients continued therapy
without dose reduction after resection. The
SCC seems to be due to a paradoxical
activation of the MAPK pathway that bypasses
BRAF inhibition, as mentioned above [10].
Following on the footsteps of vemurafenib
has been the development of other novel potent
kinase inhibitors. Dabrafenib, similar to
vemurafenib, is a potent inhibitor of mutant
V600 BRAF kinase and has also been studied in a
randomized phase III (BREAK-3) trial evaluating
its activity against dacarbazine in patients with
metastatic V600 mutated melanoma [11–13].
This trial showed significant improvement in
the primary endpoint of PFS with dabrafenib
(5.1 months) compared to dacarbazine
(2.7 months) (HR = 0.33, p\0.0001).
Dabrafenib was FDA approved for single agent
use for BRAF mutant metastatic melanoma
based on these data. An update presented at
ESMO 2014 showed a median OS of 20 and
15.6 months for the dabrafenib arm and
dacarbazine arm, respectively, but did not
reach statistical significance (HR 0.77 with
95% CI 0.52–1.13) [14]. More than half of the
patients originally treated with dacarbazine
crossed over to dabrafenib, potentially
obscuring the OS benefit.
MEK inhibitors work by inhibiting MEK1/
MEK2, a protein kinase that is just downstream
of BRAF in the MAP kinase signaling pathway.
Trametinib, which is an MEK1/MEK2 inhibitor,
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has been explored for its single-agent activity in
the randomized phase 3 METRIC trial [15]. In
this study, 322 patients with BRAF V600E/
V600K mutant metastatic melanoma who had
failed a prior chemotherapy were randomized
(2:1) to receive trametinib or chemotherapy
(choice of dacarbazine or paclitaxel). The
primary endpoint of the study was PFS. The
study was positive with the median PFS for
trametinib being 4.8 versus 1.5 months for
chemotherapy. An update presented at the
Society for Melanoma Research 2013 Congress
showed median OS of 15.6 vs. 11.5 months (HR
0.78; 95% CI 0.57–1.06), despite 65% crossover
from the chemotherapy arm to trametinib arm
[16]. Side effects of trametinib therapy included
rash, diarrhea, fatigue, dermatitis, and edema.
In May 2013, the FDA approved trametinib for
treatment of patients with unresectable or
metastatic melanoma with BRAF V600E/V600K
mutation who have not received prior BRAF
inhibitor therapy.
Overcoming Resistance to BRAF Inhibition
with Combination Molecularly Targeted
Approaches
The development of resistance to single BRAF
and MEK inhibition therapy occurs in almost all
cases of advanced melanoma with resistant
tumor cells exhibiting a reactivation of the
MAP kinase pathway. A variety of events occur
triggering this resistance including the presence
of NRAS mutations, COT-mediated MAPK
activation, redirection of signaling through
CRAF, PI3kinase pathway signaling via PTEN
loss, PDGFR upregulation or AKT3
upregulation, secretion of hepatocyte growth
factor, increased activation of FGFR3, and a
variety of other events [17–22]. Given that MAP
kinase pathway reactivation is a common cause
of single-agent BRAF inhibitor resistance, the
use of other MAP kinase inhibitors downstream
of BRAF has been an area of interest.
The proof that BRAF and MEK coinhibition
could bypass some of these resistance
mechanisms and advance clinical outcomes
was demonstrated in a phase 1/2 study
evaluating the combination of dabrafenib and
trametinib [23]. These data resulted in a series of
pivotal phase 3 trials evaluating the BRAF/MEK
inhibitor combinations. The COMBI-D trial was
a randomized, double-blind, phase 3 study
comparing the combination of dabrafenib and
trametinib to dabrafenib plus placebo as first-line
therapy in 423 patients with unresectable or
metastatic BRAFV600E/K mutant melanoma
[24]. Combination dabrafenib and trametinib
resulted in a 25% reduction in risk of progression
compared to dabrafenib alone (median PFS of 9.3
vs. 8.8 months, HR 0.75, p = 0.035). The median
PFS decreased to 7.2 months when clinical
progression and receipt of new anticancer
therapy were included in the dabrafenib alone
group. An updated OS analysis announcement
in February 2015 showed a 29% risk reduction in
death (HR = 0.71, p = 0.011) [25]. This study also
demonstrated that combining an MEK inhibitor
with BRAF inhibition can attenuate the
increased risk of cutaneous malignancies with
BRAF inhibitor therapy. Improvements in skin
toxicities were noted in the combination group,
such as squamous cell carcinoma (2% vs. 9%),
hyperkeratosis (3% vs. 32%), alopecia (7% vs.
26%), and hand-foot syndrome (5% vs. 27%).
This reduction in squamous cell carcinoma with
BRAF/MEK combination therapy has been
explained by the paradoxical activation of the
MAP kinase pathway in squamous cell
carcinoma lesions by a single-agent BRAF
inhibitor because the malignant cells harbor
RAS mutations [10]. Use of an MEK inhibitor in
this situation nullifies this pathway activation by
single-agent BRAF inhibition, thus the reduction
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in incidence of squamous cell lesions. It is
important to note that single-agent BRAF
inhibitor use does not cause squamous cell
carcinomas, but results in acceleration in
growth of pre-existing lesions. Other toxicities
were seen at higher frequencies in the
combination group, such as pyrexia (51% vs.
28%); hypertension (22% vs. 14%) and diarrhea
(24% vs. 14%) were higher in the combination
group.
The COMBI-V trial was an open-label phase 3
study that randomized patients with untreated
advanced BRAF mutant melanoma (n = 704) to
dabrafenib plus trametinib or vemurafenib
alone [26]. The median PFS favored the
combination group with a 44% risk reduction
(median PFS of 11.4 vs. 7.3 months, HR = 0.56,
p\0.001). In addition, the overall response rate
was 64% for the combination group compared
to 51% for the vemurafenib group, which was
statistically significant (p\0.001). Median
duration of response was also longer in the
combination group (13.8 months compared to
7.5 months). The OS analysis at 12 months
showed a 31% risk reduction (HR = 0.69,
p = 0.005). Similar to COMBI-D, a significant
reduction in hyperproliferative skin toxicity was
seen in the COMBI-V trial. For example, the rate
of cutaneous SCC and keratoacanthomas was
only 1% in the combination group compared to
18% for the vemurafenib group. This has
provided further evidence that combination
BRAF and MEK inhibition is superior to
single-agent BRAF inhibition. Based on the
results of COMBI-D and COMBI-V, trametinib
and dabrafenib combination therapy has
become the standard approach to patients
harboring a BRAF V600 mutation who are
considered for molecularly targeted therapy.
Following the path of dabrafenib and
trametinib, other BRAF/MEK combination
studies have been performed or are in
progress. The phase 3 coBRIM study evaluated
the combination of the MEK inhibitor,
cobimetinib, with vemurafenib. In this
double-blind phase 3 trial, 495 patients with
previously untreated unresectable stage 3 or
metastatic V600 mutant melanoma were
randomized to receive either vemurafenib plus
cobimetinib or vemurafenib plus placebo [27].
The PFS was significantly prolonged with the
combination represented by a 49% risk
reduction of progression (median PFS of 9.9 vs.
6.2 months, HR = 0.51, p\0.001). Interim OS
analysis with a 9-month survival rate showed a
35% risk reduction (HR = 0.65, 95% CI
0.42–1.00), but it did not cross the
pre-specified stopping boundary. Reductions in
secondary cutaneous neoplasms, as noted in the
other studies, were observed, and grade 3 or 4
adverse events with the combination arm were
65% as opposed to 59% in the single-agent arm.
Cobimetinib is currently under priority review
for FDA approval in combination with
vemurafenib. Finally, the COLUMBUS study is
an ongoing phase 3 randomized three-armed
trial comparing LGX818 (BRAF inhibitor) plus
MEK162 (MEK inhibitor) to LGX818 alone and
vemurafenib alone. This study may present the
therapeutic field with a third BRAF/MEK
combination option.
Other trial approaches to overcoming BRAF
pathway resistance beyond BRAF plus MEK
combinations are also being studied. A trial
evaluating an individualized molecular
approach, named the LOGIC 2 trial, is
underway that focuses on BRAFV600 mutant
melanoma patients who have progressed on the
LGX818/MEK162 combination and obtains a
new tumor biopsy after progression. Based on
the molecular findings of the progressing
tumor, the patient continues the LGX818/
MEK162 combination with an additional third
agent, which would include BKM120 (PI3k
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inhibitor), LEE011 (CDK4/6 inhibitor), BGJ398
(FGFR inhibitor) or INC280 (cMET inhibitor).
This study has the potential to show benefit of a
more individualized approach in patients with
emerging or pre-existing mutations that
promote resistance to primary MAP kinase
pathway inhibition. Studies evaluating
combinations to overcome the PI3 kinase
pathway resistance mechanism are also
ongoing (NCT01512251, NCT01902173).
Targeting Pathways in Other Melanoma
Subsets
Evaluation of targeted treatments for melanoma
patients whose tumors harbor mutations other
than BRAF is also underway. The NRAS kinase is
mutated in about 15–25% of untreated
melanoma tumors. It is seen in about 20% of
BRAF mutant patients who progressed on BRAF
inhibitor therapy, but very rarely coexists with
BRAF mutation prior to a BRAF inhibitor
exposure [28]. Like BRAF, NRAS is a driver
mutation, and it can activate multiple
downstream pathways including the MAPK
pathway through BRAF or CRAF and PI3K.
NRAS mutations are usually seen in an older
population and where chronic UV exposure has
been present. Compared to BRAF mutant
tumors, the NRAS mutation tends to be
present in thicker tumors with a higher
mitosis rate and is arguably more aggressive
than BRAF mutated tumors [29, 30]. Targeting
of RAS directly has proven challenging for drug
developers. However, since NRAS mutations
drive the MAPK pathway, downstream
inhibition of MEK appears to be a rational
approach. Trials exploring different MEK
inhibitors as well as combination approaches
with CDK 4/6 inhibitors or PI3K/AKT pathway
inhibitors are being performed for patients who
harbor NRAS mutations [31]. The results of a
phase 2 trial evaluating binimetinib (MEK162)
in patients with metastatic NRAS mutant
melanoma (n = 117) were reported in
September 2014 [32]. An ORR of 14.5% was
observed including one person who achieved
complete CR. Survival endpoints were also
reported including a median PFS of
3.6 months (95% CI 2.6–3.8 months) and a
median OS of 12.2 months (lower 95% CI of
7.9 months). Based on the efficacy noted in this
study, a randomized phase 3 trial (NEMO) was
launched and is currently ongoing in metastatic
NRAS mutant melanoma patients comparing
binimetinib to dacarbazine.
The use of MEK inhibitors may also play a
role in a rarer melanoma subtype, ocular
melanoma, which is also driven by MAP
kinase pathway activation. Ocular melanoma
is a type of melanoma typically excluded from
melanoma trials because of its notoriously
treatment-resistant nature, rapid rate of
progression, and different genetics (high
frequency of GNAQ and GNA11 mutations).
In a recently reported study, the MEK inhibitor,
selumetinib, was compared to temozolomide
chemotherapy and showed a PFS of 15.9 weeks
compared to 7 weeks, respectively (HR = 0.46,
p\0.001) [33]. Median OS was 9.1 vs.
11.8 months in the selumetinib arm (HR 0.66,
p = 0.09). Although overall survival did not
reach statistical significance, this was the first
randomized trial to show a statistical
improvement in PFS, which is a meaningful
advance forward for this disease that lacks
therapeutic options.
The growth factor receptor, c-kit, also plays
an important role in a small subset of
melanoma patients. Up to 20% of patients
with mucosal, chronic sun-damaged and acral
lentigeninous melanomas have mutations in
c-kit, which drives pathogenesis in these tumors
[34]. A variety of agents, including imatinib,
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dasatinib, sunitinib, and nilotinib potently,
inhibits the ckit receptor and trials with the
agents have either been performed or are
currently ongoing. The most experience with
targeted therapy in kit-mutant melanoma has
been with imatinib, with several phase 2 trials
being reported [35–39]. In non-enriched
patients for kit-activating mutations, the
efficacy of imatinib has been rather
disappointing; however, this is not the case in
patients who are selected by a specific activating
mutation (e.g., exon 9, 11, 13 mutations). In a
study by Hodi et al., imatinib was tested in
advanced melanoma patients with kit
mutations or amplification [38]. In this study,
the ORR was 29%, which was significantly
better than the null value of 5%. The response
rate was highest in those with activating
mutations with a 51% response rated. Median
time to progression was relatively brief
(3.9 months for the mutated group,
3.4 months for the amplified group), and
median overall survival was 12.5 months. In a
trial evaluating the kit inhibitor nilotinib,
patients with advanced melanoma harboring
kit alterations that were refractory to imatinib
were studied [40]. The response rate for this
approach was 18% with a median TTP of
3.3 months and OS of 9.1 months. Notably, no
responses were seen in a separate cohort





Similar to the field of targeted mutation-based
therapy, the field of immunotherapy in
melanoma has also changed dramatically in
the last few years. Activated CD8?
T-lymphocytes are an essential line of defense
against tumor cells. These lymphocytes require
interfacing with antigen-presenting cells via T
cell receptors (TCR), and a number of proteins
have been identified that influence the effect of
this interaction (Fig. 2) [41]. After the TCR
interaction and a secondary signal via
costimulatory molecules have activated the
lymphocyte, inhibitory molecules may be
expressed in order to limit or restrain T-cell
function (an immune checkpoint). This process
serves to protect the host from over activation
of the immune system and autoimmunity. An
important inhibitory immune checkpoint
signal involves the interaction of CD28 and
CTLA-4 (CD152) on T-cells, which act as
costimulatory and coinhibitory signals
respectively, with either CD80 (B7-1) or CD86
(B7-2) on the antigen-presenting cells.
Inhibition of a negative immune checkpoint,
such as CTLA-4, can release the negative impact
on lymphocytes, allowing them to remain
active against the tumor.
Ipilimumab, a monoclonal antibody against
the CTLA-4 protein, has been evaluated in two
landmark phase 3 clinical studies, showing
improved survival compared to vaccine
therapy in one trial and improved survival
compared to DTIC in another. In the first
study, 676 previously treated metastatic
melanoma patients were randomized 3:1:1 to
receive ipilimumab plus GP100 vaccine
(melanoma peptide vaccine), ipilimumab
alone, or GP100 vaccine alone [42]. The
primary endpoint of overall survival was
successful with the median OS being 10.0,
10.1, and 6.4 months for each arm,
respectively. Interestingly, patients who
respond to ipilimumab may develop initial
progression followed by the observed response.
This observation has led to the creation of a set
of immune response criteria that can capture
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these data, unlike the traditional RECIST
criteria. In clinical practice, this potential for
delayed response requires the clinician to often
consider continuation of therapy in the setting
of asymptomatic radiographic or clinical
progression to allow for this delayed response.
However, in cases of symptomatic progression,
waiting for delayed response can be challenging
and in certain situations impractical.
Ipilimumab therapy has also been associated
with distinctive immune-related adverse events
(IRAEs). These IRAEs can include colitis,
dermatitis, hepatitis, endocrinopathies and
neuropathies, all of which are related to an
inflammatory effect of lymphocyte activation.
While most individuals had tolerable side
effects, severe immune-related adverse events
(grade 3 or higher) were noted in 10–15% of
patients treated with ipilimumab.
Based on the results of these data, ipilimumab
was FDA approved in March 2011. A subsequent
phase 3 placebo-controlled trial evaluated 502
previously untreated patients with metastatic
melanoma using a higher dose of ipilimumab
(10 mg/kg as compared to 3 mg/kg) in
combination with dacarbazine vs. dacarbazine
alone [43]. This trial also showed a significant
improvement in its primary endpoint ofOS, with
those receiving the ipilimumab/dacarbazine
combination having a median OS of
11.2 months compared to 9.2 months for
dacarbazine alone (HR 0.72, p\0.001).
PD-1 Inhibition
Like CTLA-4, the programmed death-1 (PD-1)
receptor is an important negative regulator of
T-lymphocyte activity (inhibitory checkpoint)
[44]. PD-1 interacts with the PD-1 ligand
(PD-L1), which can be expressed on a variety
of tissue surfaces including the tumor cell
surface or tumor-infiltrating macrophages,
resulting in suppression of T-lymphocyte
function and tumor evasion of immune
regulation. Multiple studies have shown an
inverse correlation between PD-L1 expression
in tumor cells and poor prognosis in multiple
tumor types [41].
Pembrolizumab is a humanized monoclonal
IgG4 antibody that binds to PD-1, blocks the
negative interaction with PD-L1, and ultimately
results in a rejuvenation and potentiation of
T-lymphocytes, which can then have antitumor
activity. The FDA granted accelerated approval
in September 2014 for patients with unresectable
or metastatic melanoma following treatment
with ipilimumab or a BRAF inhibitor (in
V600E/K mutant melanoma), based on the
phase 1 Keynote-001 trial [45]. This trial
explored pembrolizumab therapy in 173
advanced melanoma patients who met the
criteria of progression on ipilimumab and a
BRAF inhibitor (if applicable). Pembrolizumab
demonstrated an ORR of 24% with response
duration ranging from 1.4 months to over
8.5 months. In a follow-up phase 3 trial
(Keynote-002), 540 ipilimumab refractory
patients were randomized to pembrolizumab
2 mg/kg every 3 weeks, 10 mg/kg every 3 weeks,
or chemotherapy. Results presented at the 2014
Society of Melanoma Research Congress showed
6-month PFS rates of 34, 38, and 16 percent for
the 2 and 10 mg/kg pembrolizumab arms and
the chemotherapy arm, respectively [46].
Treatment-related grade 3 or higher adverse
events occurred in 11% of patients in the 2 mg/
kg arm, 14% in the 10 mg/kg arm, and 26% with
chemotherapy. In the phase 3 Keynote-006 trial,
834 patients with unresectable or metastatic
melanoma who had received no more than one
prior systemic therapy (required to be CTLA-4
and PD-1 inhibitor naı¨ve) were randomized to
receive pembrolizumab at 10 mg/kg every
3 weeks, 10 mg/kg every 2 weeks, or 4 cycles of
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ipilimumab 3 mg/kg every 3 weeks [47]. In this
study, both pembrolizumab arms appeared to
have similar efficacy outcomes, and both were
superior to ipilimumab in the studies primary
endpoints of PFS and OS. Themedian PFS for the
q2 week pembrolizumab regimen was
5.5 months compared to 4.1 months for the
q3 week regimen and 2.8 months for
ipilimumab (HR 0.58, p\0.001 for q2 week
regimen versus ipilimumab). The median OS
has not been reached for any of the groups at the
time of publication; however, the 12-month
survival landmark demonstrated a survival of
74.1% (q2 week pembrolizumab), 68.4%
(q3 week), and 58.2% (ipilimumab). The
difference between the pembrolizumab arms
was statistically superior to ipilimumab for the
12-month OS analysis (HR 0.63).
Nivolumab is a fully humanmonoclonal PD-1
blocking antibody and has also been extensively
evaluated in a series of phase 3 trials in advanced
melanomapatients. The FDA approved the use of
nivolumab for patients with unresectable or
metastatic melanoma following treatment with
ipilimumab or a BRAF inhibitor in December
2014 based on the phase 3 CheckMate-037 study
[48]. In this trial, 405 patients were assigned to
either nivolumab or chemotherapy in a 2:1 ratio,
and the first interim analysis reported objective
responses of 31.7% (95% CI 23.5–40.8) vs. 10.6%
(95% CI 3.5–23.1) favoring nivolumab. Another
phase 3 trial (CheckMate-066) enrolled 418
patients with previously untreated metastatic
melanoma without a BRAF mutation to receive
nivolumab or dacarbazine [49]. The 1-year
landmark survival rate was 72.9% for
nivolumab compared to 42.1% for dacarbazine
(HR for death 0.42; 95%CI 0.25–0.73; p\0.001).
Median OS had not been reached for the
nivolumab group at the time of publication,
while the median OS was 10.8 months for
dacarbazine. The median PFS for nivolumab was
5.1 months compared to 2.2 months for
dacarbazine (HR 0.43, p\0.001). Additionally,
an improved ORR was noted for nivolumab of
40% compared to only 13.9% for those treated
with dacarbazine chemotherapy. The
improvements in PFS, response, and OS were
seen regardless of PD-1 ligand expression in
patient tumors. Interestingly, as with
pembrolizumab, these studies have
demonstrated responses in both
ipilimumab-pretreated and ipilimumab-naı¨ve
patients, suggesting that a lack of benefit from
ipilimumab does not preclude benefit from
anti-PD-1 therapy.
Other approaches to interfering with the
PD-1/PD-L1 interaction have been made with
the development of anti-PD-L1 antibodies. A
phase 1 trial of BMS-936559, a monoclonal
antibody that targets PD-L1, has been reported
showing activity among patients with
metastatic melanoma. In a dose escalation
trial, 55 patients with metastatic melanoma
were included with nine objective responses
(17% ORR) [50]. Among these responders were
three who had a complete response. An
additional 14 (27%) patients had stable disease
lasting more than 24 weeks. Common side
effects included infusion-related reactions
(10%), diarrhea (9%), and rash (7%). Grade 3
or higher adverse events were uncommon (9%).
Another anti-PD-L1 antibody (MPDL3280A) is
being explored in a phase 1 trial in patients with
melanoma, renal cancer, non-small-cell lung
cancer, and other tumor types [51]. Results from
the melanoma cohort (n = 44) were reported,
showing a 29% ORR in 38 evaluable patients.
The responses were durable with 10 of 11
patients continuing with therapy at the time
of study report. In this group of patients, no
dose-limiting adverse events were noted with
common adverse events including fatigue,
headache, diarrhea, and pruritus. MPDL3280A
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is currently being combined with vemurafenib





In the adjuvant setting, the EORTC 18071 trial
explored ipilimumab compared to placebo in
951 patients with stage III melanoma after wide
local excision and lymph node resection [52].
Median recurrence-free survival was 26.1 vs.
17.1 months, favoring the ipilimumab group
(hazard ratio 0.75; 95% CI 0.64–0.90;
p = 0.0013). Overall survival results remain
pending at this time; however, ipilimumab has
been submitted for FDA review for use in the
adjuvant setting. Ipilimumab is also being
explored in two other randomized phase 3
trials. The cooperative group study E1609 is
evaluating two different doses of ipilimumab,
10 mg/kg and 3 mg/kg, compared to interferon
therapy in patients with resected stage IIIB, IIIC,
and IV (M1a, b)melanoma (NCT01274338). This
study completed accrual in 2014 and is yet to be
reported. Another actively accruing trial,
CheckMate-238, compares ipilimumab (at
10 mg/kg dosing) to nivolumab in patients
with resected stage IIIB, IIIC, and IV melanoma
(NCT02388906). Finally, two separate
randomized trials evaluating pembrolizumab in
the adjuvant setting are planned to be conducted
through cooperative group mechanisms
beginning in 2015 (EORTC, SWOG).
COMBINATION IMMUNE
CHECKPOINT INHIBITORS
Single-agent PD-1 inhibition with nivolumab
and pembrolizumab has demonstrated higher
rates of activity and tolerability compared to
what has previously been seen with
ipilimumab. However, the potential for the
combination of a PD-1 inhibitor and
ipilimumab has been highlighted in a series of
phase 1, 2, and 3 trials [53–55]. In a striking
phase 1 trial, the combination of ipilimumab
and nivolumab in previously treated metastatic
melanoma patients resulted in surprising
response rates (range 21–53%) with both rapid
and deep responses noted. An update on 1- and
2-year OS rates for this trial has been presented,
and they are 82% and 75%, respectively, with a
median OS of about 40 months [56].
Additionally, of those patients obtaining a
response, the bulk of these patients is seeing
depths of tumor shrinkage of[80%, which is
durable. Grade 3 or 4 adverse events were noted
in 53% of patients, and the most common ones
were elevated lipase and AST. A phase 2 trial
confirmed the efficacy of the combination
compared to ipilimumab and has now been
published [54]. A three-arm placebo-controlled,
blinded phase 3 trial (CheckMate-067) has now
been reported, further describing the efficacy
and adverse event profile of the nivolumab/
ipilimumab combination [55]. This study
explored the front-line use of nivolumab and
ipilimumab compared to nivolumab alone and
ipilimumab alone in metastatic melanoma
patients with a primary endpoint of PFS. The
median PFS for the nivolumab/ipilimumab
combination group was significantly improved
compared to ipilimumab (11.5 versus
2.9 months, HR 0.42, p\0.001) and
numerically improved compared to nivolumab
(6.9 months). It should be noted that the trial
was not designed to evaluate statistical
difference between nivolumab single arm and
the combination arm. The status of PD-L1
expression on tumors was evaluated, and
patients were stratified based on presence
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([5% expression) or absence (\5%). There was
no difference between the combination arm
and nivolumab arms for patients expressing
PD-L1 (median PFS of 14 months for both
groups); however, in those with negative
PD-L1 expression a significant difference was
noted between the two groups (median PFS
11.2 months for combination and 5.3 months
for nivolumab alone). As expected, there was a
higher frequency of grade 3/4 events in the
combination arm (55%) compared to either
single-treatment arm (nivolumab: 16.3%;
ipilimumab: 27.3%). It is important to note
that patient toxicities in the combination arm
were could be managed safely with established
algorithms and that no patients died from
treatment-related toxicity in the combination
arm. The trial has not yet matured enough for
overall survival data.
Multiple preclinical studies and a few clinical
studies showed a synergistic benefit of CTLA-4
blockade and GM-CSF-secreting tumor cell
vaccines [57–59]. A phase 2 randomized trial
enrolled 245 previously treated unresectable
stage 3 or metastatic melanoma patients to
ipilimumab plus sargramostim vs. ipilimumab
alone [60]. At median follow-up duration of
13 months, there was no difference in PFS;
however, the median OS significantly favored
the sargramostim group at 17.5 versus
12.7 months. The 1-year OS rate for the
combination was 68.9% compared to 52.9%
for ipilimumab alone (HR 0.64, p = 0.01).
Interestingly, there was a reduction of toxicity
in the combination group, particularly
gastrointestinal and pulmonary adverse events.
The proposed mechanism for improved efficacy
that resulted in increased OS is theorized to be
an improved antigen presentation with GM-CSF
via recruitment of dendritic cells and
macrophages. However, it is also possible that
the improved toxicity profile also may have
impacted outcomes.
One unanswered question in the BRAF V600
mutated subset of melanoma patients is
whether to use initial therapy focused on the
BRAF pathway, target immune checkpoints or
utilize a combination of these approaches.
There are a variety of trials seeking to answer
these questions, including trials comparing
upfront ipilimumab and nivolumab versus
dabrafenib and trametinib followed by
cross-over on progression (NCT02224781),
combining nivolumab with dabrafenib and/or
trametinib (NCT02357732), and combining
pembrolizumab with dabrafenib and
trametinib (NCT02130466).
OTHER AGENTS IN DEVELOPMENT
A variety of other approaches are being pursued
for melanoma therapy that can activate the
immune system in other ways. One agent that
has been tested in a phase 3 trial is talimogene
laherparepvec, also known as TVEC. This agent
is a modified herpes simplex virus that has been
designed to replicate in tumor cells and
transcribe granulocyte macrophage
colony-stimulating factor (GM-CSF) [61]. The
virus must be directly injected into tumors
where it can multiply and cause cell lysis and
release of GM-CSF into the tumor
microenvironment. The GM-CSF can then
attract immune cells such as dendritic cells
that can stimulate an anticancer immune
response. TVEC has been studied in a phase 3
trial of 436 metastatic or unresectable
melanoma patients who were randomized to
receive either T-VEC intratumoral injections or
subcutaneous GM-CSF [62]. The primary
endpoint was a durable response rate with
secondary endpoints of the overall response
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rate and overall survival. The durable response
rate for TVEC was noted to be 16.3% compared
to 2.1% for GM-CSF (p\0.01). The response
rate was also higher at 26.4% compared to 5.7%.
A trend toward improved overall survival was
noted but not statistically significant
(p = 0.051). Common side effects with T-VEC
included fatigue, chills, and pyrexia. TVEC has
been submitted to the FDA for approval;
however, final FDA approval is pending.
Criticisms of the study include the GM-CSF
control arm, which was given the treatment
subcutaneously rather than intra-tumorally.
Additionally, GM-CSF is known to have no
significant activity in melanoma as a single
agent. Finally, the clinical significance of these
trial results compared to study results of the
previously immune checkpoint agents and
targeted therapies, which have shown more
impressive survival outcomes, is unclear. TVEC
is currently being studied in combination with
pembrolizumab in advanced melanoma
patients.
In addition to CTLA-4 and PD-1, there are
numerous other immune checkpoints. These
include activating checkpoints such as OX-40,
GITR, and CD137 as well as inhibiting
checkpoints such as TIM-3 and LAG-3.
Antibodies to these immune checkpoint
receptors have been created and are in early
development in clinical trials. Positive clinical
activity from these trials would certainly make
combination approaches with currently
available drugs an exciting challenge in the
future. Novel cytokine therapy development
has also been recently undertaken.
Interleukin-15 (IL-15) is a cytokine that
activates T-cell lymphocytes and natural killer
(NK) cells. The cytokine IL-15 has been studied
in a phase 1 trial in advanced melanoma and
renal cell carcinoma patients [63]. Dose-limiting
toxicities that were seen included hypotension,
thrombocytopenia, and liver transaminase
elevation. Activity was seen in two patiets
with lung metastases. ALT-803 is a novel
engineered compound in development that
activates the IL-15 receptor, but has been
shown to have improved biologic activity and
longer half-life than IL-15. It is currently in a
phase I dose escalation trial in patients with
advanced melanoma.
Finally, adoptive T-cell therapy is an
investigational approach to immunotherapy,
which has been under study for over several
decades [64]. The adoptive T-cell approach has
traditionally required resection of tumor tissues
and isolation of tumor-infiltrating lymphocytes
(TILs). The TILs are then grown in culture in the
laboratory, activated or enhanced in vitro, and
given back to the patient by infusion often
along with interleukin-2 therapy. While this
approach has shown response rates between
approximately 30–50% in small trials in
melanoma patients, it has remained a very
laborious treatment that can be done at only a
few select centers in the world. New approaches
including instilling chimeric antigen receptors
on the surface of peripherally obtained
lymphocytes (CAR-T cells) that target certain
cancers may be a more practical method of
introducing this novel cellular therapy into the
clinic. These chimeric antigen receptors can be
designed to recognize common proteins on the
malignant cell, which thereby can activate an
immune response in vivo. Studies evaluating
CAR-T cells are underway in a variety of
different cancer types.
CONCLUSION
It is currently an exciting time for metastatic
melanoma clinical research, with six new drugs
FDA approved in the last 4 years (Table 1). Each
of these has shown single-agent activity in
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improving overall survival for patients with this
devastating cancer. These agents are
additionally being explored as adjuvant
therapies for patients with high-risk resected
stage III patients. For BRAF mutant melanomas,
the combination of BRAF inhibitor and MEK
inhibitor has become the standard approach
because of the superior survival outcomes
compared to single-agent BRAF inhibitors. In
addition, evaluation of unique combinations of
agents such as PI3K, AKT, CDK4, and ERK
inhibitors may prove valuable for patients who
develop resistance to BRAF/MEK inhibitors
based on early work evaluating the molecular
mechanisms of BRAF inhibitor resistance.
Targeted approaches for non-BRAF mutant
Fig. 2 Schematic diagram showing select immune
checkpoint interactions between T-cells and tumor or
antigen-presenting cells. There are several important
receptors that are expressed on the T-lymphocyte that
can either up- or downregulate T-cell activity. Depicted are
select important immune checkpoint receptors and their
corresponding ligands for which drug development is
ongoing. Examples of immune checkpoint receptors that
downregulate T-cell function are CTLA-4, PD-1, and
TIM-3. Immune checkpoint receptors that upregulate
T-cell function are OX-40, GITR, and CD-40. Blockade
of CTLA-4 (ipilimumab) or PD-1 (nivolumab or
pembrolizumab) results in the sustained activity of
T-lymphocyte function and enhanced tumor cell
destruction
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melanoma patients are also ongoing, including
MEK inhibitors for patients with NRAS
mutations and c-kit inhibitors for patients
with these c-kit mutations. Certainly critical to
the success of the targeted therapy tactic is an
improved understanding of the drivers of
resistance to targeted drugs, which would
allow for development of further
individualized molecular approaches in later
lines of therapy. Immune checkpoint inhibition
has been explored in parallel with molecularly
targeted drugs and has shown significant
improvement in patients with advanced
melanoma. Ipilimumab, nivolumab, and
pembrolizumab are currently approved as
single agents for advanced melanoma because
of their ability to extend survival outcomes.
However, combinational approaches such as
combining immune checkpoint inhibitors
with each other, with other immunotherapies,
and with molecularly targeted drugs may
expand on these outcomes. Based on recent
positive clinical studies, it is anticipated that
nivolumab and pembrolizumab will become
FDA approved in the front-line setting, and
potentially the nivolumab and ipilimumab
combination will also become approved. The
optimal sequence and combination of targeted
drugs and immunotherapies are still unknown
and remain an active area of clinical research.
One area of concern is the potential cost burden
that these new agents may introduce for
patients and society. For example, a course of
ipilimumab has the potential to cost over
$100,000. The other immune checkpoint
inhibitors and oral targeted agents also have a
similar degree of cost, particularly if patients
remain on them for many months. For patients
receiving no benefit high costs add an extra
burden; however, for patients that achieve
long-term survival these costs may be viewed
through a different lens, and a positive return
for the high cost is more tangible. Although
many factors go into the cost of drugs,
including the price of development of new
agents, this issue drives the need for improved
biomarkers to help select patients who would
benefit from a particular agent so that patients
who will not benefit can avoid both the toxicity
of the drug as well as the cost.
With that said, it is difficult to deny that the
advances that have been made in therapeutic
development for metastatic melanoma over the
last fewyears are quite astonishing. The sharp rise
in response rates from 10% with the older drugs
to[50%withnewer agents has given the treating
physician agents which are much more likely to
palliate cancer-related symptoms and thus
improve quality of life. Additionally, these new
drugs have extended survival of the average
patient, which over the last several decades has
never been done before. Not only is the average
survival of the metastatic melanoma patient
improving for the first time in history, but there
is a large, currently undefined subset of patients
who have the potential to experience a long term
survival advantage measured in years, not
months. Of all things, this gives us hope, that as
we progress towards an improved understanding
of how to use these currently approved and
upcoming drugs, we will see the elimination of
this once dismal disease in our lifetime.
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